Sakar Healthcare vs Peers
- Market cap
- ₹2,214 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹716.40 – ₹1,343.25
Sakar Healthcare ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Sakar Healthcare. Its P/E of 22.5 compares with a peer median of 22.5.
Sakar Healthcare vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Sakar Healthcare | 995.00 | -2.46% | 2,214 | 22.5 | 2.85 | 14.5% | +18.5% |
| Sakar Healthcare | 995.00 | -2.46% | 2,214 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Sakar Healthcare peer comparison — frequently asked questions
Who are Sakar Healthcare's competitors?
Sakar Healthcare's listed peers in Drug Manufacturers - Specialty & Generic include Sakar Healthcare, ranked here by market capitalisation.
How does Sakar Healthcare's P/E compare with its peers?
Sakar Healthcare trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Sakar Healthcare's peers?
By market capitalisation, the largest company in the group is Sakar Healthcare at ₹2,214 crore, against ₹2,214 crore for Sakar Healthcare.
Same Data For Peers
Trade Sakar Healthcare With ATS
Track SAKAR live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.